Vaccinex Inc

NASDAQ:VCNXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Sep 18, 2024

Show headlines and story abstract

• Top Midday Decliners, from 1:54PM ET on Wednesday Sep 18, 2024 by MT Newswires

  1:54PM ET on Wednesday Sep 18, 2024 by MT Newswires
  Companies Mentioned: CBUS, VCNX, MULN
  01:54 PM EDT, 09/18/2024 (MT Newswires) -- Cibus (CBUS) said Wednesday it priced an underwritten public offering of 3 million shares of its class A common stock at $4 apiece, targeting gross proceeds of about $12 million. Shares slumped 28% amid int...

• Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds, from 8:30AM ET on Wednesday Sep 18, 2024 by Dow Jones

  8:30AM ET on Wednesday Sep 18, 2024 by Dow Jones
  Companies Mentioned: VCNX
  
  Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
  
  ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, announced today the entry into definitive agreements for the immediate exercise of outstanding warrants to purchase an aggregate of 1,067,492 shares of common stock (the "Existing Warrants") at the reduced exercise price of $5.636 per share, resulting in the issuance of 827,483 shares and the pre-funding of 240,009 shares.